AI
BPMC

Atria Investments’s Blueprint Medicines BPMC Stock Holding History

Atria Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,491
Closed -$220K – 1994
2025
Q1 		$220K Buy
+2,491
New +$243K ﹤0.01% 1777
2024
Q3 		– Sell
-1,940
Closed -$209K – 1912
2024
Q2 		$209K Buy
+1,940
New +$194K ﹤0.01% 1800

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atria Investments's BPMC Position: Q2 2025 in Review

Atria Investments sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 2,491 shares — an estimated $220K sold.

Atria Investments first reported a position in BPMC in Q2 2024 and held it in 2 quarters. The position peaked at $220K in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Atria Investments reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Atria Investments sold 2,491 Blueprint Medicines shares in Q2 2025, an estimated $220K.
  • Atria Investments first reported a position in Blueprint Medicines in Q2 2024 and held it in 2 quarters.
  • Atria Investments's Blueprint Medicines position peaked at $220K in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Atria Investments's 13F filing for Q2 2025, filed 4 Aug 2025.